Recombinant antithymocyte globulin - GigaGen
Alternative Names: Recombinant human ATG - GigaGenLatest Information Update: 28 Nov 2024
At a glance
- Originator GigaGen
- Class Polyclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Renal transplant rejection
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for research development in Renal-transplant-rejection(Prevention) in USA (Parenteral)
- 24 Nov 2022 GigaGen has multiple patents for Surge and Magnify Platform worldwide (GigaGen pipeline, November 2022)
- 17 Oct 2022 Early research is still ongoing for Renal transplant rejection (Prevention) in USA (Parenteral) (GigaGen pipeline, October 2022)